Although traditional renin-angiotensin system antagonists including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of cardiovascular disease (CVD), the pivotal PARADIGM-HF trial demonstrated that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), was superior to an angiotensin-converting enzyme inhibitor in reducing cardiovascular morbidity and mortality in patients with heart failure and reduced ejection fraction. However, despite international regulatory approval and strong recommendations in the guidelines, uptake of sacubitril/valsartan has been disappointing. Sacubitril/valsartan is now the focus of a large programme of clinical trials testing the hypothesis that ARNIs may supplant conventional renin-angiotensin system inhibitors across the spectrum of CVD, including hypertension, secondary prevention after myocardial infarction, and heart failure with preserved ejection fraction. This review summarizes the existing evidence, knowledge gaps, and future directions of ARNIs in CVD based on discussions between clinical trialists, industry representatives, and
Introduction
The prognosis of patients with cardiovascular disease (CVD) has been revolutionized by guideline-directed medical therapies.
1
Although traditional renin-angiotensin system (RAS) antagonists, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have been the cornerstone of therapy for CVD for several decades, 2 the PARADIGM-HF trial demonstrated that substitution of an ACEI (i.e. enalapril) with an angiotensin receptor-neprilysin inhibitor (ARNI) (i.e. sacubitril/valsartan) led to a 20% relative reduction in the risk of cardiovascular death or heart failure (HF) hospitalization in patients with chronic, stable HF with reduced ejection fraction (HFrEF). 3, 4 bitril/valsartan in CVD and to discuss completed, ongoing, and planned clinical trials in HFrEF, HF with preserved ejection fraction (HFpEF), post-myocardial infarction (MI), and hypertension ( Table 3) .
Heart failure with reduced ejection fraction
PARADIGM-HF

Study overview
The PARADIGM-HF trial was designed to test the hypothesis that inhibiting neprilysin, thereby preventing the degradation of natriuretic and many other vasoactive peptides, in addition to blocking angiotensin II type 1 receptors, would reduce cardiovascular morbidity and mortality in patients with HFrEF compared to an ACEI used in guideline-recommended doses. 3 Patients aged ≥18 years with chronic HFrEF [ejection fraction (EF) ≤35-40%] and New York Heart Association (NYHA) functional class II-IV symptoms, an elevated B-type natriuretic peptide (BNP) or N-terminal pro BNP (NT-proBNP), an estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m 2 , and a stable dose of a beta-blocker and an ACEI/ARB equivalent to at least 10 mg of enalapril daily were eligible for enrolment.
A total of 10 521 patients entered sequential single-blind run-in periods with enalapril 10 mg twice daily for 2 weeks followed by sacubitril/valsartan initially at a dose of 100 mg (i.e. currently marketed as 49/51 mg tablet) twice daily uptitrated to 200 mg (i.e. 97/103 mg tablet) twice daily for 4 to 6 weeks. Following the run-in phase, 8442 patients (80%) who had tolerated both interventions and who were still willing and able to participate were randomized in a 1:1 fashion to double-blind treatment with either enalapril 10 mg twice daily or sacubitril/valsartan 200 mg twice daily. 7 
Efficacy of sacubitril/valsartan
On 28 March 2014 after the third interim analysis, the data and safety monitoring board notified the principal investigators that the boundary for overwhelming benefit had been crossed and the executive committee voted to stop the trial early. 4 At the time the study was terminated, enrolment had been completed and there was a median follow-up duration of 27 months. Patients receiving sacubitril/valsartan (914 events, 21.8%), compared to enalapril (1117 events, 26.5%), were at lower risk for the primary outcome, death due to cardiovascular causes or first hospitalization for HF [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.73-0.87; P < 0.001], as well as each of the components of the composite endpoint (Figure 1) . Treatment with sacubitril/valsartan (711 events, 17.0%) vs. enalapril (835 events, 19.8%) also led to a significant reduction in all-cause mortality (HR 0.84, 95% CI 0.76-0.93; P < 0.001). Based on the PARADIGM-HF data and actuarial estimates of event rates and life expectancy, it has been projected that treatment with sacubitril/valsartan would prolong survival an average of 1 to 2 years across a wide range of age groups. 8 Although health-related quality of life, as assessed by the change in the Kansas City Cardiomyopathy Questionnaire (KCCQ clinical summary score from baseline to 8 months, declined in both treatment arms during follow-up, it worsened to a greater extent in the enalapril arm. 9 However, when zero values were not imputed for patients who died, the magnitude of the between-group difference (0.95 points, 95% CI 0.31-1.59; P = 0.004) was greatly diminished suggesting that the KCCQ analyses were confounded by the competing risk of death. Additional research is required to evaluate the impact of angiotensin receptor-neprilysin inhibition on health-related quality of life and functional capacity.
Safety and tolerability of sacubitril/valsartan
Patients receiving sacubitril/valsartan experienced higher rates of symptomatic hypotension vs. enalapril (14.0% vs. 9.2%; P < 0.001)
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( Figure 2) . However, there were no differences between the sacubitril/valsartan and enalapril groups in permanent study drug discontinuation due to hypotension (0.9% vs. 0.7%; P = 0.38). The incidence of renal insufficiency (i.e. defined as a serum creatinine ≥2.5 mg/dL) and hyperkalaemia during follow-up was lower in patients treated with sacubitril/valsartan compared to enalapril. In addition, the occurrence of minor and life-threatening episodes of angioedema was low (<0.5%) and did not differ between treatment groups. Of note, as a condition for approval, the FDA has required Novartis Pharma AG (Basel, Switzerland) to conduct an observational registry to further clarify the risk of angioedema in black patients treated with sacubitril/valsartan vs. conventional RAS inhibitors (New Drug Application 207620 Approval, accessdata.fda.gov).
Finally, because neprilysin plays a role in removing amyloid-peptides from the brain, it has been postulated that long-term treatment with an ARNI might affect cognitive function.
11 Despite this theoretical concern, neprilysin is only one of more than 20 enzymes involved in amyloid-clearance. There was no discernible signal of increased risk of dementia with sacubitril/valsartan, compared to enalapril, in the PARADIGM-HF trial. However, additional research is required to evaluate the association between treatment with sacubitril/valsartan and mild cognitive impairment in patients with additional risk factors for dementia as well as over a longer duration of follow-up. 12 Thus, as part of the FDA approval process, the manufacturer will conduct a multicentre, randomized, double-blind, active-controlled trial to evaluate the effects of sacubitril/valsartan vs. valsartan on cognitive function as assessed by comprehensive neurocognitive testing and brain imaging (New Drug Application 207620 Approval, accessdata.fda.gov).
Real-world adoption of sacubitril/valsartan
Despite receiving FDA approval and strong recommendations in international guidelines, the uptake of sacubitril/valsartan in routine practice has been disappointing. The AHA's Get With The Guidelines-Heart Failure (GWTG-HF) registry found that based on FDA labelling, nearly 70% of patients hospitalized for HFrEF (i.e. EF ≤40%) would be eligible for sacubitril/valsartan. 13 Similarly, data from the United Kingdom suggest that upwards of 60% of outpatients consecutively referred to a community HF clinic would be eligible for ARNI therapy.
14 In contrast, only 2.3% of patients hospitalized for HFrEF were prescribed sacubitril/valsartan at discharge in the first 12 months following FDA approval. 15 Some estimates suggest that optimal implementation of ARNI therapy could prevent more than 28 000 deaths per year. 16 Given the relative efficacy and safety profile of sacubitril/valsartan compared to conventional RAS inhibitors, it is important to carefully consider provider reasons for not prescribing, system level barriers to implementation, and patient factors for decision-making with respect to this life-prolonging therapy.
Stability on traditional renin-angiotensin system inhibitors
There is a clinical inertia among providers and a resistance to change among patients if things seem to be going well and the situation is stable.
17 However, the PARADIGM-HF trial found that HF is a lethal syndrome, regardless of the severity of symptoms, as evidenced by the high short-term mortality rate seen in a minimally symptomatic patient population. Despite the fact that nearly 40% of patients had no prior hospitalization for HF, one in five of these patients died due to cardiovascular causes or were hospitalized for HF during follow-up. 18 In addition to improving survival, sacubitril/valsartan, compared to enalapril, reduced the risk of clinical deterioration including hospitalizations (HR 0.79, 95% CI 0.71-0.89; P < 0.001), emergency department visits (HR 0.66, 95% CI 0.52-0.58; P = 0.001), and/or intensification of medical therapy in the outpatient setting (HR 0.84, 95% CI 0.74-0.94; P = 0.003) for worsening HF. sacubitril/valsartan arm. 21 Thus, given the dissociation between HF signs and symptoms and prognosis and the overwhelming benefit of sacubitril/valsartan on both fatal and non-fatal endpoints, there is not a clear rationale to wait for clinical progression or deterioration before switching patients from traditional RAS inhibitors to an ARNI.
Validity of the PARADIGM-HF trial
Another potential reason for clinical aversion to switching patients to sacubitril/valsartan may be reservations regarding the design of the PARADIGM-HF trial. 22 It has been argued that enalapril and/or the target dose used in the PARADIGM-HF trial were not the gold standard comparator. However, this is the only dose of any ACEI that has been shown in a clinical trial to improve long-term survival. 23 Although CONSENSUS tested a higher target dose of enalapril (i.e. 40 mg daily), less than 25% of patients reached the highest dose and the mean daily dose of enalapril achieved in PARADIGM-HF was actually marginally higher (i.e. 18.9 mg vs. 18.6 mg). 24, 25 Thus, any difference between sacubitril/valsartan and enalapril in terms of outcomes is likely to be due to the addition of neprilysin inhibition.
Reproducibility of the PARADIGM-HF trial
It has also been argued that PARADIGM-HF was a single trial and the results need to be replicated before ARNI therapy supplants traditional RAS inhibitors as the standard of care. However, the idea of carrying out a hypothetical PARADIGM-HF-2 may be both unethical and unnecessary. If PARADIGM-HF was divided at the chronological midpoint into two distinct clinical trials and 6 An ACEI is recommended in addition to a beta-blocker for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.
I A Sacubitril/valsartan is recommended as a replacement for an ACEI to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACEI, beta-blocker, and MRA.
I B
An ARB is recommended to reduce the risk of HF hospitalization and CV death in symptomatic patients unable to tolerate ACEI (patients should also receive a beta-blocker and an MRA).
An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate an MRA.
IIb C ACC, American College of Cardiology; ACEI, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; COR, class (strength) of recommendation; CV, cardiovascular; EO, expert opinion; ESC, European Society of Cardiology; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFSA, Heart Failure Society of America; LOE, level of evidence; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; R, randomized. * Level of evidence for an ARNI.
the results re-examined, despite the loss of statistical power, the outcomes of both smaller trials would be identical to the parent trial. 22 The statistical power of PARADIGM-HF was equal to or greater than that of four separate clinical trials each showing a reduction in cardiovascular mortality with a P-value of <0.05. The possibility that the primary results were due to chance is less than one in one million. 26 This assertion is further substantiated by a meta-analysis of pooled data from three clinical trials in HFrEF (i.e. IMPRESS, OVERTURE, and PARADIGM-HF), which found that combined neprilysin-RAS inhibition (i.e. omapatrilat or sacubitril/valsartan) compared to traditional RAS inhibition improved survival.
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Cost considerations with sacubitril/valsartan
Another patient and system level barrier to implementation and widespread adoption of sacubitril/valsartan is cost. 28 The estimated wholesale price of twice-daily dosing of sacubitril/valsartan in the United States is $12.50 per day costing upwards of $4500 annually. 29 However, it is difficult to estimate true out-of-pocket expenses as there is tremendous variation based on insurance status and level of reimbursement. the medical record and paperwork for prior authorization, placing an additional burden on prescribers. In contrast, although the cost of the therapy may be substantial for patients and health care payers, it should be pointed out that several analyses have found sacubitril/valsartan to be cost-effective compared to conventional RAS inhibitors (i.e. traditionally defined as less than $50 000 per quality-adjusted life year) in HFrEF patients with NYHA functional class II-IV symptoms.
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Use of sacubitril/valsartan in primary care
Although the 2016 ACC/AHA/HFSA focused update recommends ARNI therapy as a first-line alternative to traditional RAS inhibitors in patients with HFrEF who remain symptomatic despite optimal medical therapy, 5, 6 the American Academy of Family Physicians has not yet endorsed this guideline because of concerns about its methodology and insufficient evaluation of harm. 33 Due to their advanced age and multiple co-morbidities, it is not uncommon for HFrEF patients to receive regular care from general practitioners and multiple specialists and subspecialists. Many primary care physicians may treat a significant number of patients with HFrEF and some may be the primary provider for HF-related care in addition to general medical conditions. It is confusing ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; CVM, cardiovascular mortality; EF, ejection fraction; GDMIT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; i.v., intravenous; MI, myocardial infarction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; VO Figure 1 Forest plots for the primary, secondary, and exploratory outcomes of the PARADIGM-HF trial. CV, cardiovascular; ER, emergency room; HF, heart failure.
and counterproductive to general practitioners when a discrepancy exists between the guideline recommendations published by cardiologists and HF specialists and the public statements issued by their own professional societies. As a result, increasing the uptake of sacubitril/valsartan in the outpatient setting may require providing continuing medical education focused on the specific needs and concerns of primary care physicians. The experience with sacubitril/valsartan is a learning opportunity and moving forward guideline committees addressing topics in cardiology and HF should include physicians with training in internal and/or family medicine who are currently practicing and selected to represent the viewpoint and serve as a liaison for their respective professional organizations.
LIFE
Although sacubitril/valsartan was broadly approved by the FDA for the management of patients with HFrEF (i.e. defined as an EF ≤40%) and NYHA functional class II-IV symptoms, it is noteworthy that only 33 patients (0.8%) with NYHA functional class IV symptoms were randomized to sacubitril/valsartan. Thus, the LIFE study (ClinicalTrials.gov Identifier: NCT02816736) is a randomized, double-blind, active-controlled trial designed to assess the efficacy, safety, and tolerability of sacubitril/valsartan in a planned 400 patients with HFrEF and severe symptoms. Although it is difficult to define advanced HF, the LIFE trial requires one or more enrichment criteria as objective evidence of advanced HF, including need for inotropic support, repeat hospitalizations, and assessments of functional capacity. In addition, both treatment arms in the LIFE trial differ in clinically important ways compared to PARADIGM-HF. First, the LIFE trial will make use of a lower dose of sacubitril/valsartan (i.e. 24/26 mg tablet by mouth twice daily), which was not used in PARADIGM-HF. This will allow a better assessment of the safety and tolerability of this lower dose, particularly with respect to symptomatic hypotension. Second, the comparator arm is valsartan, an ARB, as opposed to enalapril, the gold standard ACEI. This will potentially allow a more direct interpretation of the effects of neprilysin inhibition in isolation. However, it should be noted that the selection of valsartan for the control arm has been criticized given the limited experience with ARBs in HFrEF patients with NYHA functional class IV symptoms compared to ACEIs. Despite these strengths, the primary endpoint of the LIFE trial will assess time-averaged change in a surrogate biomarker (i.e. NT-proBNP). While natriuretic peptide levels are strongly correlated with adverse events, 34 the trial will be underpowered to draw definitive conclusions on hard clinical outcomes. In addition, recruitment may be challenging given that one of the first harbingers of advanced HF is an inability to tolerate guideline-directed medical therapies.
PIONEER-HF
The PIONEER-HF study (ClinicalTrials.gov Identifier: NCT02554890) is a multicentre trial designed to assess the role of sacubitril/valsartan in patients with HFrEF stabilized during hospitalization for worsening HF. Patients are eligible for enrolment no earlier than 24 h and up to 10 days from initial presentation for a primary diagnosis of HF if they have an EF ≤40%, an elevated BNP or NT-proBNP, and are clinically stable (i.e. defined as a systolic blood pressure ≥ 100 mmHg and no recent intensification in intravenous therapies). Patients are randomized 1:1 to in-hospital initiation of sacubitril/valsartan vs. enalapril titrated to target dose over 8 weeks of double-blind treatment and 4 weeks of open-label sacubitril/valsartan using an algorithm based on systolic blood pressure. The primary endpoint of PIONEER-HF is the time-average proportional change in NT-proBNP from baseline through weeks 4 and 8. Secondary and exploratory endpoints include urgent and emergent episodes of care and serum and urinary biomarkers of myocardial stress, cardiac fibrosis/remodelling, inflammation, and tissue perfusion/injury. There are several unique aspects of the PIONEER-HF study which will further explore the application of sacubitril/valsartan in routine practice. Of note, PIONEER-HF was designed to enrol patients hospitalized for worsening HF following stabilization irrespective of duration of diagnosis or background HF therapy and without a preceding run-in period. Thus, this will be the first opportunity to assess the safety and tolerability of in-hospital initiation of sacubitril/valsartan in de novo HF and in a treatment naïve patient population. In addition, the secondary endpoints of PIONEER-HF move beyond traditional outcome measures by incorporating worsening HF treated in the outpatient setting including unscheduled office, urgent care, and emergency department visits. The available data suggest that including unscheduled or urgent episodes of care not leading to hospitalization in the composite clinical endpoint may increase the total number of accrued events by upwards of 15%. Heart failure with preserved ejection fraction
PARAMOUNT and PARAGON-HF
The PARAMOUNT trial was designed to assess the therapeutic value of sacubitril/valsartan in HFpEF. 35 Patients were eligible if they had an EF ≥45% and a history of HF with associated signs and symptoms and an elevated NT-proBNP. Following a run-in phase, 301 patients were randomized 1:1 in a double-blind fashion to treatment with valsartan 160 mg twice daily (n = 152) or sacubitril/valsartan 200 mg twice daily (n = 149). The PARAMOUNT trial was continued for 36 weeks including the 12-week main study period and a 24-week extension phase. The primary efficacy endpoint was change in NT-proBNP from baseline to week 12.
Treatment with sacubitril/valsartan, compared to valsartan, led to an early and sustained reduction in NT-proBNP through week 12. Although NT-proBNP levels continued to decrease in patients treated with sacubitril/valsartan, the between-group difference was no longer statistically significant at 36 weeks (P = 0.20). In addition, after 36 weeks of treatment with sacubitril/valsartan, compared to valsartan, left atrial volume and dimension were both significantly reduced. However, there was no difference in EF, ventricular volumes, or other diastolic parameters. Patients treated with sacubitril/valsartan also experienced an improvement in NYHA functional class at 36 weeks compared to the valsartan arm.
PARAGON-HF (ClinicalTrials.gov Identifier: NCT01920711), a cardiovascular outcomes trial of sacubitril/valsartan in HFpEF, has fully enrolled over 4800 patients with a planned follow-up duration of up to 57 months for the composite endpoint of cardiovascular mortality and total hospitalizations for worsening HF. 36 Although the results of the PARAGON-HF trial are highly anticipated, it is notoriously difficult to make the assessment that dyspnoea in a patient with a preserved EF is due to HF and not a co-morbid condition (i.e. obesity, chronic obstructive pulmonary disease, sleep disordered breathing, etc.). The experience with the TOPCAT study further highlights the challenges of designing and conducting global clinical trials in HFpEF. 37, 38 In short, the TOPCAT investigators found tremendous geographic variation in patient characteristics, outcomes, and response to therapy that may have been partially explained by differential regional enrolment in the prior hospitalization vs. BNP strata. 39, 40 As a result, it is notable that participation in PARAGON-HF is contingent upon the presence of signs and symptoms of HF requiring treatment with a diuretic, evidence of structural heart disease (i.e. defined as left atrial enlargement and/or left ventricular hypertrophy), and an elevated NT-proBNP in order to improve diagnostic accuracy and enrol a sufficiently high-risk patient population. In contrast to prior pivotal trials in HFpEF, the control arm of PARAGON-HF is an active comparator (i.e. valsartan) as opposed to placebo as ARBs are commonly prescribed and have been shown to be safe in HFpEF and may lead to a modest reduction in hospitalizations for worsening HF. 41 In addition, the use of an active comparator will allow the neurohormonal benefits of neprilysin inhibition to be studied in isolation from RAS blockade in HFpEF. The major limitation of the PARAGON-HF trial is that requiring objective evidence of structural heart disease and an elevated NT-proBNP may limit its generalizability. It is well-established that upwards of 30% of patients with symptomatic HFpEF may have a normal BNP in the setting of an elevated pulmonary capillary wedge pressure. 42 In addition, prior research has shown that although elevated BNP/NT-proBNP levels may denote an overall higher risk HFpEF cohort, these patients may be less responsive to treatment. 43, 44 Thus, there may be a dissociation between disease severity and response to therapy in HFpEF which requires further exploration. Regardless, the PARAGON-HF trial will determine whether the short-term effects of sacubitril/valsartan on cardiac injury, 45 myocardial stress, and left atrial remodelling translate into improved long-term prognosis in an adequately powered cardiovascular outcomes study.
Post-myocardial infarction PARADISE-MI
The PARADISE-MI trial (ClinicalTrials.gov Identifier: NCT02924727) will test the hypothesis that ARNI therapy will reduce cardiovascular morbidity and mortality compared to conventional RAS inhibition in post-MI patients with additional risk factors. PARADISE-MI will enrol patients diagnosed with a spontaneous acute MI with an EF ≤40% and/or pulmonary congestion requiring intravenous therapy, one or more enrichment criteria, and documented haemodynamic stability. An estimated 4650 patients will be randomized 1:1 to double-blind treatment with sacubitril/valsartan vs. ramipril and followed for the composite of . The PARADISE-MI trial follows a strong precedent whereby traditional RAS inhibitors were first studied in the setting of chronic HF and later found to be equally beneficial in post-MI patients with evidence of systolic dysfunction and/or signs and symptoms of HF. 46 -50 However, due to the widespread availability of early revascularization and advances in medical therapy, the incidence of previously asymptomatic patients experiencing a MI complicated by a reduced EF and/or pulmonary oedema has declined dramatically over time. For example, in a national quality improvement registry of patients admitted for acute coronary syndrome, less than 20% of patients had a moderately-severely reduced EF (i.e. <40%). 51 Thus, although the enrichment criteria will likely be necessary to identify patients at sufficiently high risk to ensure an adequately powered study, this requirement may also make it more challenging to recruit patients and limit the generalizability of the findings.
Hypertension
The combination of neprilysin inhibition and RAS blockade has also been explored as a treatment for hypertension. In a phase II study, 1328 patients with mild-to-moderate essential hypertension were randomized to sacubitril/valsartan, valsartan, or placebo. 52 After 8 weeks of treatment, sacubitril/valsartan, compared to the appropriate comparator dose of valsartan, led to a greater reduction in mean diastolic blood pressure (-2.17 mmHg, 95% CI -3.28,-1.06 mmHg; P = 0.0023). The difference was significant for all pairwise comparisons except for the lowest dose of sacubitril/valsartan vs. valsartan.
Despite the strong evidence basis for aggressive blood pressure control in high-risk individuals, epidemiologic data suggest that the standard blood pressure goal is achieved in only 50% of patients. 53 Thus, treating hypertension to achieve goal blood pressure remains an important public health objective and an unmet therapeutic need. Given the demonstrated superiority of ARNI therapy compared to conventional RAS inhibitors as an anti-hypertensive agent, pivotal trials should be designed and conducted to study the efficacy and safety of sacubitril/valsartan as a monotherapy and as part of combination therapy in patients with hypertension and risk factors for CVD as well as medically refractory hypertension. 54 
Conclusion
Despite major therapeutic advances in the management of CVD, post-MI patients with evidence of systolic dysfunction or symptomatic HF irrespective of EF receiving optimal medical therapy including traditional RAS inhibitors remain at high risk for cardiovascular morbidity and mortality. The PARADIGM-HF trial demonstrated that ARNI therapy, compared to an ACEI, led to a robust benefit on both fatal and non-fatal endpoints, independent of baseline risk and current clinical status in patients with HFrEF and predominantly mild symptoms. Thus, the available data suggest there is little rationale to wait for clinical progression or deterioration and it is reasonable to switch stable HFrEF patients with minimal
